drugset / Trial / NCT00712504
Study Of SU011248 In Combination With Docetaxel In Patients With Advanced Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study is determining the maximum tolerated dose and safety of SU011248 (sunitinib malate, SUTENT) in combination with docetaxel (Taxotere). Several dosing regimens will be tested in patients with advanced solid tumors, including non small cell lung cancer.
Timeline
- Start
- 2004-07
- Primary completion
- 2007-11
- Completion
- 2007-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Docetaxel | Small molecule | 60 mg/m2 | Intravenous |
| Subject | Docetaxel | Small molecule | 75 mg/m2 | Intravenous |
| Subject | Docetaxel | Small molecule | 100 mg/m2 | Intravenous |
| Subject | Sunitinib | Small molecule | 25 mg | Oral |
| Subject | Sunitinib | Small molecule | 37.5 mg | Oral |
| Subject | Sunitinib | Small molecule | 50 mg | Oral |